Haematological malignancies following temozolomide treatment for paediatric high-grade glioma
Background: Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
3 June 2017
|
| In: |
European journal of cancer
Year: 2017, Jahrgang: 81, Pages: 1-8 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.04.023 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2017.04.023 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917309504 
|
| Verfasserangaben: | Michael Karremann, Nadja Krämer, Marion Hoffmann, Maria Wiese, Andreas Beilken, Selim Corbacioglu, Dagmar Dilloo, Pablo Hernáiz Driever, Wolfram Scheurlen, Andreas Kulozik, Gerrit H. Gielen, André O. von Bueren, Matthias Dürken, Christof M. Kramm |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577338936 | ||
| 003 | DE-627 | ||
| 005 | 20240316100453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180705s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.04.023 |2 doi | |
| 035 | |a (DE-627)1577338936 | ||
| 035 | |a (DE-576)507338936 | ||
| 035 | |a (DE-599)BSZ507338936 | ||
| 035 | |a (OCoLC)1341013523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Karremann, Michael |d 1975- |e VerfasserIn |0 (DE-588)129089192 |0 (DE-627)389523534 |0 (DE-576)166957968 |4 aut | |
| 245 | 1 | 0 | |a Haematological malignancies following temozolomide treatment for paediatric high-grade glioma |c Michael Karremann, Nadja Krämer, Marion Hoffmann, Maria Wiese, Andreas Beilken, Selim Corbacioglu, Dagmar Dilloo, Pablo Hernáiz Driever, Wolfram Scheurlen, Andreas Kulozik, Gerrit H. Gielen, André O. von Bueren, Matthias Dürken, Christof M. Kramm |
| 264 | 1 | |c 3 June 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.07.2018 | ||
| 500 | |a Available online 3 June 2017 | ||
| 520 | |a Background: Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. Methods: We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. Results: The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. Conclusion: Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing. | ||
| 650 | 4 | |a Children | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a High-grade glioma | |
| 650 | 4 | |a Secondary haematological malignancies | |
| 700 | 1 | |a Kohl, Nadja |d 1990- |e VerfasserIn |0 (DE-588)1162313056 |0 (DE-627)1025891708 |0 (DE-576)507338626 |4 aut | |
| 700 | 1 | |a Kulozik, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1025736567 |0 (DE-627)723892032 |0 (DE-576)167091638 |4 aut | |
| 700 | 1 | |a Dürken, Matthias |d 1961- |e VerfasserIn |0 (DE-588)1034398431 |0 (DE-627)745449670 |0 (DE-576)382004787 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 81(2017), Seite 1-8 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Haematological malignancies following temozolomide treatment for paediatric high-grade glioma |
| 773 | 1 | 8 | |g volume:81 |g year:2017 |g pages:1-8 |g extent:8 |a Haematological malignancies following temozolomide treatment for paediatric high-grade glioma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2017.04.023 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804917309504 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180705 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1034398431 |a Dürken, Matthias |m 1034398431:Dürken, Matthias |d 60000 |e 60000PD1034398431 |k 0/60000/ |p 13 | ||
| 998 | |g 1025736567 |a Kulozik, Andreas |m 1025736567:Kulozik, Andreas |d 910000 |d 910500 |e 910000PK1025736567 |e 910500PK1025736567 |k 0/910000/ |k 1/910000/910500/ |p 10 | ||
| 998 | |g 1162313056 |a Kohl, Nadja |m 1162313056:Kohl, Nadja |d 60000 |d 62300 |e 60000PK1162313056 |e 62300PK1162313056 |k 0/60000/ |k 1/60000/62300/ |p 2 | ||
| 998 | |g 129089192 |a Karremann, Michael |m 129089192:Karremann, Michael |d 60000 |d 62300 |e 60000PK129089192 |e 62300PK129089192 |k 0/60000/ |k 1/60000/62300/ |p 1 |x j | ||
| 999 | |a KXP-PPN1577338936 |e 3016243571 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","family":"Karremann","display":"Karremann, Michael","given":"Michael"},{"given":"Nadja","display":"Kohl, Nadja","role":"aut","family":"Kohl"},{"given":"Andreas","role":"aut","family":"Kulozik","display":"Kulozik, Andreas"},{"given":"Matthias","family":"Dürken","role":"aut","display":"Dürken, Matthias"}],"language":["eng"],"note":["Gesehen am 05.07.2018","Available online 3 June 2017"],"origin":[{"dateIssuedDisp":"3 June 2017","dateIssuedKey":"2017"}],"name":{"displayForm":["Michael Karremann, Nadja Krämer, Marion Hoffmann, Maria Wiese, Andreas Beilken, Selim Corbacioglu, Dagmar Dilloo, Pablo Hernáiz Driever, Wolfram Scheurlen, Andreas Kulozik, Gerrit H. Gielen, André O. von Bueren, Matthias Dürken, Christof M. Kramm"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1577338936","id":{"doi":["10.1016/j.ejca.2017.04.023"],"eki":["1577338936"]},"title":[{"title":"Haematological malignancies following temozolomide treatment for paediatric high-grade glioma","title_sort":"Haematological malignancies following temozolomide treatment for paediatric high-grade glioma"}],"physDesc":[{"extent":"8 S."}],"relHost":[{"part":{"text":"81(2017), Seite 1-8","pages":"1-8","year":"2017","volume":"81","extent":"8"},"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"266883400","id":{"zdb":["1468190-0"],"eki":["266883400"],"issn":["1879-0852"]},"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"display":"European School of Oncology","role":"isb"}],"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-"}],"disp":"Haematological malignancies following temozolomide treatment for paediatric high-grade gliomaEuropean journal of cancer","language":["eng"],"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"]}]} | ||
| SRT | |a KARREMANNMHAEMATOLOG3201 | ||